ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03419650
Previous Study | Return to List | Next Study

Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS) (CLIPS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03419650
Recruitment Status : Not yet recruiting
First Posted : February 2, 2018
Last Update Posted : March 6, 2018
Sponsor:
Collaborator:
Mallinckrodt
Information provided by (Responsible Party):
Guillermo Valenzuela, MD, IRIS Research and Development, LLC

Brief Summary:
Demonstrate the clinical value of Acthar TM in patients with active Psoriatic Arthritis who lack adequate response to DMARDS, and the quantification of response by clinical, serologic and structural parameters.

Condition or disease Intervention/treatment Phase
Psoriatic Arthritis Drug: ACTHar Phase 4

Detailed Description:

The study is an investigator initiated study (IIS) single arm treatment, single center where patients will receive active treatment with ActharTM 80 units twice weekly for 4 weeks followed by 40 units twice weekly until week 12.

2-End points:

1.Primary Clinical Endpoint

1. To demonstrate the efficacy of Acthar for the treatment of patients with active psoriatic arthritis and who have not had an adequate response to non-biological DMARDs based on the proportion of subjects achieving a 20% improvement in the number of tender and number of swollen joints, and a 20% improvement in three of the following five criteria: patient global assessment, physician global assessment, Health Assessment Questionnaire (HAQ), visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP) as described by American College of Rheumatology (ACR) 20 at week 12.

[Time Frame: 12 weeks]

2.Primary Imaging Endpoints

  1. The improvement of the total DEMRIQ*-Volume score of synovial inflammation measured in the Metacarpophalangeal (MCP), proximal interphalangeal (PIP) and the distal interphalangeal (DIP) joints. [Time Frame: baseline to week 24]

    [Time Frame: baseline to week 24]

  2. Secondary Outcome Measures:

Secondary Imaging Endpoints

1. The improvement in PSAMRIS* Synovitis score in the Metacarpophalangeal (MCP), proximal interphalangeal (PIP) and the distal interphalangeal (DIP) joints. [Time Frame: baseline to week 24]

[Time Frame: baseline to week 24]


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Intervention Model: Single Group Assignment
Intervention Model Description: treatment arm will then be observed.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS)
Estimated Study Start Date : March 26, 2018
Estimated Primary Completion Date : December 31, 2019
Estimated Study Completion Date : December 31, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Treatment arm
treatment arm for 12 weeks followed by observation period of 12 weeks, and a bone density at week 52.
Drug: ACTHar
Acthar™ 80 units twice a week for 4 weeks followed by 40 units twice a week until week 12.
Other Name: acthar gel




Primary Outcome Measures :
  1. Primary Clinical Endpoint [ Time Frame: 12 weeks ]
    1. To demonstrate the efficacy of Acthar for the treatment of patients with active psoriatic arthritis and who have not had an adequate response to non-biological DMARDs based on the proportion of subjects achieving a 20% improvement in the number of tender and number of swollen joints, and a 20% improvement in three of the following five criteria: patient global assessment, physician global assessment, Health Assessment Questionnaire (HAQ), visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP) as described by American College of Rheumatology (ACR) 20 at week 12.

  2. Primary Imaging Endpoints [ Time Frame: baseline to week 24 ]
    1. The improvement of the total DEMRIQ*-Volume score of synovial inflammation measured in the Metacarpophalangeal (MCP), proximal interphalangeal (PIP) and the distal interphalangeal (DIP) joints. [Time Frame: baseline to week 24]


Secondary Outcome Measures :
  1. Secondary Imaging Endpoints [ Time Frame: baseline to week 24 ]
    1. The improvement in PSAMRIS* Synovitis score in the Metacarpophalangeal (MCP), proximal interphalangeal (PIP) and the distal interphalangeal (DIP) joints. [Time Frame: baseline to week 24]



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Signed written informed consent before any study-related procedure is undertaken that is not part of the standard subject management
  2. Subjects are willing to comply with the structure of the study, such as visits, treatment plan, laboratory and imaging studies.

    Clinical evidence of psoriatic arthritis defined by at least 6 months of CASPAR defined criteria (evidence of current psoriasis, a personal history of psoriasis, or a family history of psoriasis. Current psoriasis is defined as psoriatic skin or scalp disease present today as judged by a rheumatologist or dermatologist. A personal history of psoriasis is defined as a history of psoriasis that may be obtained from a patient, family physician, dermatologist, rheumatologist, or other qualified health care provider. A family history of psoriasis is defined as a history of psoriasis in a first- or second-degree relative according to patient report, and the number of tender and swollen joints as later specified. Typical psoriatic nail dystrophy including onycholysis, pitting, and hyperkeratosis observed on current physical examination.

    c. A negative test result for the presence of rheumatoid factor by any method, according to the local laboratory reference range.

    d. Either current dactylitis, defined as swelling of an entire digit, or a history of dactylitis recorded by a rheumatologist.

    e. Radiographic evidence of juxtaarticular new bone formation, appearing as ill-defined ossification near joint margins (but excluding osteophyte formation) on plain radiographs of the hand or foot.

    Current psoriasis is assigned a score of 2; all other features are assigned a score of 1.

    The subject must have active arthritis at both screening and baseline, as defined by having both:

    • Tender/painful joints on motion (out of 68 joints assessed); and;
    • Swollen joints (out of 66 joints assessed). The subject must have active Plaque Psoriasis, which has been diagnosed, or confirmed by a rheumatologist or dermatologist and the ability to use skin biopsy as a diagnostic method.
  3. Previous use of DMARDS:

    The practices for the administration of DMARD therapy, including laboratory testing, contraceptive requirements, follow-up care and contraindications should be performed according to local standards of care such as the ACR recommendations for monitoring for the duration of the study. Subjects should remain on a stable dose of that traditional DMARD throughout the course of the study.

    Methotrexate: Maximum dose of 15 mg/week. Minimum duration of therapy 3 months and dose stable for 4 weeks prior to first dose of the study. Subjects on methotrexate should be on an adequate and stable dose of folate supplementation.

    Sulfasalazine: Maximum dose of 3 gm/day. Minimum duration of therapy 2 months and dose stable for 4 weeks prior to first dose of study drug.

    Leflunomide: Maximum dose of 20 mg/day. Minimum duration of therapy 4 months and dose stable for 4 weeks prior to first dose of study drug.

    Plaquenil Azathioprine

  4. Concomitant treatments:

    Corticosteroids up to 10 mg/day prednisone or prednisone equivalent are allowed for 4 weeks stable dose before the study and can be tapered according to the investigator criteria of clinical response. NSAIDS and COX 2 medications can be used in clinically accepted doses and in stable doses 4 weeks prior to screening. Topical keratolytics such as corticosteroids, tars, anthralin, vitamin D analogs, and retinoids must be discontinued 2 weeks prior to the screening date. Non-medicated emollients including 1% hydrocortisone for palms and soles are allowed. UV light therapy needs to be discontinued 2 weeks prior to screening, and PUVA 4 weeks prior to screening.

  5. A male participant must agree to use and to have their female partners use a highly effective form of contraception, one day before the first dose of study treatment (as appropriate), during the treatment period, and refrain from donating sperm during this period.
  6. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: age related amenorrhea for at least one year, and increased follicle-stimulating hormone (FSH) >40 Miu/Ml or who have undergone hysterectomy or bilateral oophorectomy are exempt from pregnancy testing.

A woman of childbearing potential is defined as a female capable of becoming pregnant. It is also defined as any female who has experienced menarche and is not permanently sterile or postmenopausal. Postmenopausal is defined as 12 consecutive months with no menses without alternative medical cause.

Women of childbearing potential must agree to at least one method of birth control: a barrier method together or alone with a highly effective method to prevent pregnancy four weeks prior to randomization, throughout the study.

The definition of highly effective contraception includes:

  • Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation; oral, intravaginal or transdermal,
  • Progestogen-only hormonal contraception associated with inhibition of ovulation; oral, injectable or implantable,
  • Intrauterine device,
  • Intrauterine hormone-releasing system,
  • Bilateral tubal occlusion,
  • Vasectomized partner, or
  • Sexual abstinence. b. Supplementary barrier methods include:
  • Male or female condom with or without spermicide, or
  • Cap, diaphragm or sponge with spermicide, c. Men must agree to use and have their female partners use a barrier method together with a highly effective contraceptive method as defined above.

Exclusion Criteria:

  1. Other forms of psoriasis than plaque psoriasis.
  2. Any person in direct relation to the study site such as employees or family members.
  3. Breast feeding females, pregnant females or women in childbearing age not using adequate contraception.
  4. Subjects participating in other concomitant investigational protocols.
  5. Concurrent forms of severe, progressive disease such as renal, hepatic, hematological, gastrointestinal, pulmonary, neurologic and metabolic.
  6. Blood cell count below 9g/dl of hemoglobin, wbc count of less than 3000/cubic millimeters, neutropenia of less than 1500/cubic millimeter, platelet count below 100,000/cubic millimeter.
  7. Creatinine clearance of less than 40ml/min
  8. Total bilirubin or transaminases 1.5 the normal value.
  9. Known immunodeficiency
  10. Subjects with other known autoimmune rheumatic disorder such as (Systemic Lupus Erythematosus (SLE), Mixed Connective Tissue Disease (MCTD)), or other known inflammatory disorders like gout, Lyme disease, infectious disorders.
  11. History of Infected prosthesis
  12. History of lymphoprolipherative disorder
  13. History of recurrent disseminated herpetic infections.
  14. Active infections, recent hospitalization for a condition requiring intravenous antibiotics, for three months since discharge.
  15. Any form of biologic agent or patients who are active on chemotherapy or chemotherapy or any biologic within 6 months of the last treatment dose.
  16. Alcohol abuse unless documented remission for more than 6 months
  17. Acute psychiatric disorders or conditions that can alter the judgment of the subject.
  18. Active Hepatitis B, and/or Hepatitis C.
  19. Within one month prior to Screening, vaccination with live or live-attenuated virus vaccine.
  20. Allergy to porcine derived substances, participants with congestive heart failure, and with osteoporosis are also excluded from the trial.

MRI related exclusion criteria In addition to the subjects matching the inclusion/exclusion criteria above, patients meeting any of the below must be excluded from the study.

  • Known allergy to gadolinium or any of the excipients contained in the MRI contrast agent
  • History of allergy
  • Any metal objects e.g. Shrapnel, any surgical clips, pacemakers, pins, plates, screws, metal sutures or wire mesh also including uterine coil.
  • Claustrophobia
  • Morbid Obesity (BMI > 40kg/m2)
  • Cochlear implants Caution is required for patients with tattoos: the patient should inform the MRI technician site staff, who will then be able to assess whether it is sage for the patient to undergo the MRI scan.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03419650


Contacts
Contact: Kathy I Perez, MD 9544762338 ext 219 kperez@irisrheumatology.com

Sponsors and Collaborators
IRIS Research and Development, LLC
Mallinckrodt

Responsible Party: Guillermo Valenzuela, MD, Rheumatologist, IRIS Research and Development, LLC
ClinicalTrials.gov Identifier: NCT03419650     History of Changes
Other Study ID Numbers: AC0014
First Posted: February 2, 2018    Key Record Dates
Last Update Posted: March 6, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by Guillermo Valenzuela, MD, IRIS Research and Development, LLC:
PsA

Additional relevant MeSH terms:
Arthritis
Arthritis, Psoriatic
Joint Diseases
Musculoskeletal Diseases
Spondylarthropathies
Spondylarthritis
Spondylitis
Spinal Diseases
Bone Diseases
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Adrenocorticotropic Hormone
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs